About this Journal Submit a Manuscript Table of Contents
Journal of Oncology
Volume 2010 (2010), Article ID 361836, 7 pages
http://dx.doi.org/10.1155/2010/361836
Review Article

Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises

1Division of Hematology and Oncology, Department of Medicine, The George Washington University Medical Center, 2150 Pennsylvania Avenue Northwest, Washington, DC 20037, USA
2Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
3Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Received 31 October 2009; Accepted 30 December 2009

Academic Editor: Arkadiusz Dudek

Copyright © 2010 Jeanny B. Aragon-Ching et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. I. F. Tannock, R. de Wit, W. R. Berry, et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain, et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Weidner, P. R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman, “Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma,” American Journal of Pathology, vol. 143, no. 2, pp. 401–409, 1993. View at Scopus
  5. J. Folkman, “Tumor angiogenesis: therapeutic implications.,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. View at Scopus
  6. J. Folkman, K. Watson, D. Ingber, and D. Hanahan, “Induction of angiogenesis during the transition from hyperplasia to neoplasia,” Nature, vol. 339, no. 6219, pp. 58–61, 1989. View at Scopus
  7. D. Hanahan and J. Folkman, “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis,” Cell, vol. 86, no. 3, pp. 353–364, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Bergers, K. Javaherian, K.-M. Lo, J. Folkman, and D. Hanahan, “Effects of angiogenesis inhibitors on multistage carcinogenesis in mice,” Science, vol. 284, no. 5415, pp. 808–812, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Bergers and D. Hanahan, “Modes of resistance to anti-angiogenic therapy,” Nature Reviews Cancer, vol. 8, no. 8, pp. 592–603, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Hattori, B. Heissig, Y. Wu, et al., “Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment,” Nature Medicine, vol. 8, no. 8, pp. 841–849, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Pettersson, J. A. Nagy, L. F. Brown, et al., “Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor,” Laboratory Investigation, vol. 80, no. 1, pp. 99–115, 2000. View at Scopus
  13. M. Shibuya, “Vascular permeability/vascular endothelial growth factor,” in Angiogenesis: An Integrative Approach from Science to Medicine, J. Folkman and W. D. Figg, Eds., pp. 89–98, Springer, New York, NY, USA, 2008.
  14. N. Ferrara, R. D. Mass, C. Campa, and R. Kim, “Targeting VEGF-A to treat cancer and age-related macular degeneration,” Annual Review of Medicine, vol. 58, pp. 491–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. K. J. Kim, B. Li, J. Winer, et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,” Nature, vol. 362, no. 6423, pp. 841–844, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. H.-P. Gerber and N. Ferrara, “Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies,” Cancer Research, vol. 65, no. 3, pp. 671–680, 2005. View at Scopus
  17. S. F. Shariat, V. A. Anwuri, D. J. Lamb, N. V. Shah, T. M. Wheeler, and K. M. Slawin, “Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1655–1663, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Borre, B. V. Offersen, B. Nerstrom, and J. Overgaard, “Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting,” British Journal of Cancer, vol. 78, no. 7, pp. 940–944, 1998. View at Scopus
  19. M. Borre, S. M. Bentzen, B. Nerstrom, and J. Overgaard, “Tumor cell proliferation and survival in patients with prostate cancer followed expectantly,” Journal of Urology, vol. 159, no. 5, pp. 1609–1614, 1998. View at Scopus
  20. D. G. Bostwick, T. M. Wheeler, M. Blute, et al., “Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies,” Urology, vol. 48, no. 1, pp. 47–57, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. L. A. Mucci, A. Powolny, E. Giovannucci, et al., “Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study,” Journal of Clinical Oncology, vol. 27, pp. 5627–5633, 2009.
  22. Thalidomide FDA Approval—National Cancer Institute, October 2009, http://www.cancer.gov/cancertopics/druginfo/thalidomide.
  23. R. J. D'Amato, M. S. Loughnan, E. Flynn, and J. Folkman, “Thalidomide is an inhibitor of angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 9, pp. 4082–4085, 1994. View at Scopus
  24. B. M. Kenyon, F. Browne, and R. J. D'Amato, “Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization,” Experimental Eye Research, vol. 64, no. 6, pp. 971–978, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Dredge, J. B. Marriott, C. D. Macdonald, et al., “Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects,” British Journal of Cancer, vol. 87, no. 10, pp. 1166–1172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. W. D. Figg, W. Dahut, P. Duray, et al., “A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer,” Clinical Cancer Research, vol. 7, no. 7, pp. 1888–1893, 2001. View at Scopus
  27. B. A. Teicher, E. A. Sotomayor, and Z. D. Huang, “Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease,” Cancer Research, vol. 52, no. 23, pp. 6702–6704, 1992. View at Scopus
  28. W. D. Figg, P. Arlen, J. Gulley, et al., “A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer,” Seminars in Oncology, vol. 28, no. 4, supplement 15, pp. 62–66, 2001. View at Scopus
  29. W. L. Dahut, J. L. Gulley, P. M. Arlen, et al., “Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer,” Journal of Clinical Oncology, vol. 22, no. 13, pp. 2532–2539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. W. D. Figg, A. Retter, S. M. Steinberg, and W. L. Dahut, “In reply,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 2113–2114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. W. L. Dahut, J. B. Aragon-Ching, S. Woo, et al., “Phase I study of oral lenalidomide in patients with refractory metastatic cancer,” Journal of Clinical Pharmacology, vol. 49, no. 6, pp. 650–660, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. P. Petrylak, K. Resto-Garces, M. Tibyan, et al., “A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 27, supplement 15, 2009, abstract 5156.
  33. “A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer,” October 2009, http://clinicaltrials.gov/ct2/show/NCT00942578?term=lenalidomide+and+docetaxel+and+bevacizumab&rank=1.
  34. Bevacizumab approval: National Cancer Institute, October 2009, http://www.cancer.gov/cancertopics/druginfo/bevacizumab.
  35. K. J. Kim, B. Li, K. Houck, J. Winer, and N. Ferrara, “The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies,” Growth Factors, vol. 7, no. 1, pp. 53–64, 1992. View at Scopus
  36. D. M. Reese, P. Fratesi, M. Corry, W. Novotny, E. Holmgren, and E. J. Small, “A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer,” Prostate Journal, vol. 3, no. 2, pp. 65–70, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. C. J. Ryan, A. M. Lin, and E. J. Small, “Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale,” Urologic Oncology, vol. 24, no. 3, pp. 250–253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Picus, S. Halabi, B. Rini, et al., “The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006,” Proceedings of the American Society of Clinical Oncology, vol. 22, p. 392, 2003.
  39. Y. M. Ning, P. M. Arlen, J. L. Gulley, et al., “Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC),” Journal of Clinical Oncology, vol. 26, supplement 20, 2008, abstract 5000.
  40. “Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy,” October 2009, http://clinicaltrials.gov/ct2/show/NCT00110214?term=prostate+avastin+docetaxel&rank=3.
  41. J. Holash, S. Davis, N. Papadopoulos, et al., “VEGF-Trap: a VEGF blocker with potent antitumor effects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11393–11398, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. H.-P. Gerber, T. H. Vu, A. M. Ryan, J. Kowalski, Z. Werb, and N. Ferrara, “VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation,” Nature Medicine, vol. 5, no. 6, pp. 623–628, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Ferrara, H. Chen, T. Davis-Smyth, et al., “Vascular endothelial growth factor is essential for corpus luteum angiogenesis,” Nature Medicine, vol. 4, no. 3, pp. 336–340, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. Q. S.-C. Chu, “Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors,” Expert Opinion on Biological Therapy, vol. 9, no. 2, pp. 263–271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Isambert, G. Freyer, S. Zanetta, et al., “A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results,” Journal of Clinical Oncology, vol. 26, supplement 15, 2008, abstract 3599.
  46. “Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE),” October 2009, http://www.clinicaltrials.gov/ct2/show/NCT00519285?term=Aflibercept+prostate&rank=1.
  47. A. Arora and E. M. Scholar, “Role of tyrosine kinase inhibitors in cancer therapy,” Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 3, pp. 971–979, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Wilhelm and D.-S. Chien, “BAY 43-9006: preclinical data,” Current Pharmaceutical Design, vol. 8, no. 25, pp. 2255–2257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. S. M. Wilhelm, C. Carter, L. Tang, et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. W. L. Dahut, C. Scripture, E. Posadas, et al., “A phase II clinical trial of sorafenib in androgen-independent prostate cancer,” Clinical Cancer Research, vol. 14, no. 1, pp. 209–214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. J. B. Aragon-Ching, L. Jain, J. L. Gulley, et al., “Final analysis of a phase II trial using sorafenib for metastaticcastration-resistant prostate cancer,” British Journal of Urology International, vol. 103, no. 12, pp. 1636–1640, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. K. N. Chi, S. L. Ellard, S. J. Hotte, et al., “A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer,” Annals of Oncology, vol. 19, no. 4, pp. 746–751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Colloca, F. Checcaglini, and A. Venturino, “About sorafenib in castration-resistant prostate cancer,” Annals of Oncology, vol. 19, no. 10, pp. 1812–1813, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. K. N. Chi and L. Seymour, “Reply to the letter “About sorafenib in castration-resistant prostate cancer” by G. Colloca, F. Checcaglini and A. Venturino,” Annals of Oncology, vol. 19, no. 10, pp. 1813–1814, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Steinbild, K. Mross, A. Frost, et al., “A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV,” British Journal of Cancer, vol. 97, no. 11, pp. 1480–1485, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. M. R. Safarinejad, “Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study,” Urologic Oncology, vol. 28, no. 1, pp. 21–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Q. M. Chow and S. G. Eckhardt, “Sunitinib: from rational design to clinical efficacy,” Journal of Clinical Oncology, vol. 25, no. 7, pp. 884–896, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Dror Michaelson, M. M. Regan, W. K. Oh, et al., “Phase II study of sunitinib in men with advanced prostate cancer,” Annals of Oncology, vol. 20, no. 5, pp. 913–920, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. S. R. Wedge, J. Kendrew, L. F. Hennequin, et al., “AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer,” Cancer Research, vol. 65, no. 10, pp. 4389–4400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. C. J. Ryan, W. M. Stadler, B. Roth, et al., “Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC),” Investigational New Drugs, vol. 25, no. 5, pp. 445–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. J. Karakunnel, J. L. Gulley, P. M. Arlen, et al., “Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC),” Journal of Clinical Oncology, vol. 26, supplement 15, 2008, abstract 5136.
  62. R. S. Kerbel, “Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents,” BioEssays, vol. 13, no. 1, pp. 31–36, 1991. View at Scopus
  63. K. Hida, Y. Hida, D. N. Amin, et al., “Tumor-associated endothelial cells with cytogenetic abnormalities,” Cancer Research, vol. 64, no. 22, pp. 8249–8255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. O. Casanovas, D. J. Hicklin, G. Bergers, and D. Hanahan, “Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors,” Cancer Cell, vol. 8, no. 4, pp. 299–309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. K. D. Miller, C. J. Sweeney, and G. W. Sledge Jr., “The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era,” Annals of Oncology, vol. 14, no. 1, pp. 20–28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. B. I. Rini, V. Weinberg, L. Fong, S. Conry, R. M. Hershberg, and E. J. Small, “Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy,” Cancer, vol. 107, no. 1, pp. 67–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. “Late-Breaking Science Forum: Review of the Provenge Trial,” October 2009, http://www.aua2009.org/program/lbsciforum.asp.
  68. B. P. Schneider, M. Radovich, and K. D. Miller, “The role of vascular endothelial growth factor genetic variability in cancer,” Clinical Cancer Research, vol. 15, no. 17, pp. 5297–5302, 2009. View at Publisher · View at Google Scholar · View at Scopus